Promedior
Global research-led healthcare company operating integrated pharmaceuticals and diagnostics divisions. Provides end-to-end R&D across small molecules and multiple biologic modalities, develops in‑vitro diagnostic assays and laboratory instruments, and builds digital health and data platforms to support prevention, diagnosis, treatment and monitoring. Reports large-scale diagnostics distribution and substantial R&D investment; emphasises external partnerships, distributed innovation engines and ethical standards in research.
Industries
Nr. of Employees
medium (51-250)
Promedior
Lexington, Massachusetts, United States, North America
Patents
Products
Clinical in‑vitro diagnostic assays and test kits
IVD assays for infectious disease, oncology, cardiometabolic and other clinical applications available in formats suitable for central laboratories and near‑patient use.
Laboratory instrument platforms and automation systems
High‑throughput core laboratory analyzers and near‑patient devices designed to integrate automation, sample throughput and instrument maintenance features.
Digital pathology and image analysis toolsets
Whole‑slide imaging, algorithm suites and analytics to standardise pathology workflows and provide adjunctive decision support.
Clinical in‑vitro diagnostic assays and test kits
IVD assays for infectious disease, oncology, cardiometabolic and other clinical applications available in formats suitable for central laboratories and near‑patient use.
Laboratory instrument platforms and automation systems
High‑throughput core laboratory analyzers and near‑patient devices designed to integrate automation, sample throughput and instrument maintenance features.
Digital pathology and image analysis toolsets
Whole‑slide imaging, algorithm suites and analytics to standardise pathology workflows and provide adjunctive decision support.
Services
Clinical trial operations, protocol design and late‑stage development support across therapeutic areas to prepare regulatory filings and approvals.
Workflow, automation and operations solutions for laboratories, including middleware, sample tracking and analytics to improve efficiency and traceability.
Development and deployment of digital algorithms, remote monitoring modules and decision‑support tools delivered via cloud and app platforms for clinicians and patients.
Frameworks for external collaboration, startup acceleration and co‑development arrangements to pilot new technologies and integrate external innovation into development projects.
Clinical trial operations, protocol design and late‑stage development support across therapeutic areas to prepare regulatory filings and approvals.
Workflow, automation and operations solutions for laboratories, including middleware, sample tracking and analytics to improve efficiency and traceability.
Development and deployment of digital algorithms, remote monitoring modules and decision‑support tools delivered via cloud and app platforms for clinicians and patients.
Frameworks for external collaboration, startup acceleration and co‑development arrangements to pilot new technologies and integrate external innovation into development projects.
Expertise Areas
- Pharmaceutical R&D across small molecules and multiple biologic modalities
- In‑vitro diagnostics development and laboratory automation
- Clinical trial design, operations and late‑stage development
- Biomarker discovery and genomic profiling
Key Technologies
- Next‑generation sequencing and real‑time sequencing analysis
- Monoclonal and bispecific antibody engineering
- Antibody‑drug conjugate design
- Cell therapy and CAR‑T platforms
News & Updates
Ad hoc release reporting positive Phase III results for fenebrutinib as a potential BTK inhibitor in relapsing and primary progressive multiple sclerosis.
Press release reporting positive Phase III invasive disease‑free survival results for an oral selective estrogen receptor degrader in early breast cancer.
Regulatory approval of a subcutaneous formulation for relapsed or refractory follicular lymphoma.
Investor update summarising unprecedented Phase III results for a BTK inhibitor candidate in relapsing and primary progressive multiple sclerosis.
Announcement of planned presentations covering the haematology portfolio at ASH 2025.
Investor update reporting Phase III results showing significant reduction in disease activity for systemic lupus erythematosus.
Ad hoc release reporting positive Phase III results for fenebrutinib as a potential BTK inhibitor in relapsing and primary progressive multiple sclerosis.
Press release reporting positive Phase III invasive disease‑free survival results for an oral selective estrogen receptor degrader in early breast cancer.
Regulatory approval of a subcutaneous formulation for relapsed or refractory follicular lymphoma.
Investor update summarising unprecedented Phase III results for a BTK inhibitor candidate in relapsing and primary progressive multiple sclerosis.
Announcement of planned presentations covering the haematology portfolio at ASH 2025.
Investor update reporting Phase III results showing significant reduction in disease activity for systemic lupus erythematosus.